ReviewPharmaceutics2025
Pharmacological Management of Cancer Pain: Advances in Treatment Strategies and Drug Delivery Systems.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer pain seriously damages the quality of life of patients, and its management urgently needs new strategies with both efficacy and safety. This review deeply analyzes the clinical limitations of WHO's third-order analgesic strategy in cancer pain management, especially emphasizes the unique value of integrated traditional Chinese and Western medicine in synergy and reduction in adverse reactions, and summarizes the network interaction of related drugs through the regulation of multi-target analgesic mechanisms such as inflammatory factors, ion channels, neurotransmitters, and even glial cells and osteoclast activity in the tumor microenvironment. Building on this foundation, the article systematically analyzed the clinical advantages and limitations of drug delivery systems (DDS): oral sustained and controlled drug delivery system, mucosal drug delivery system (MDDS), transdermal drug delivery system (TDDS), and intrathecal targeted drug delivery (ITDD) in the treatment of cancer pain for the first time. The development prospects of new DDS: microneedles, disposable intrathecal drug delivery, and nano-drug delivery system (NDDS) in cancer pain were summarized in detail. Looking ahead, research into the analgesic mechanisms of drugs holds promise for providing a theoretical foundation for cancer pain management. Collaborative strategies integrating Chinese and Western medicine, coupled with precision delivery technologies, are expected to advance more efficient and safer pain control, offering new approaches and methods for achieving superior pain management outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.